The Weekly Litigation News Digest is now live. Subscribe now

IP Verse

Anavex Life Sciences competitive analysis

Loading summary...

Latest patents of Anavex Life Sciences opposed by its competitors

Explore Anavex Life Sciences's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Nov 13, 2025
Patent NumberPublication DateTitleTotal Oppositions
EP3324956
Nov 20, 2024Enantiomers Of Tetrahydro-N,N-Dimethyl-2,2-Diphenyl-3-Furanmethanamine (Anavex2-73) And Use Thereof In The Treatment Of Alzheimer'S Disease And Other Disorders Modulated By The Sigma 1 Receptor1
EP3407880
Aug 17, 2022Neurodevelopmental Disorder Therapy1

Latest PTAB cases involving Anavex Life Sciences

Discover the latest PTAB cases involving Anavex Life Sciences, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Anavex Life Sciences with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Nov 13, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
ANAVEX LIFE SCIENCES - 2 - -
ELKINGTON AND FIFE92 - - -
SANDOZ1191619 -